Wall Street remains bullish on the stock. All eight analysts covering Ligand rate it a buy, with a consensus price target of $244.33 implying 29% upside from the current $189 share price. The company ...
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results